Salute e Benessere

NTG Nordic Transport Group launches share buy-back program

Company announcement no. 38 – 233 August 2023 NTG Nordic Transport Group launches share buy-back program The Board of Directors of NTG has decided to launch a share buy-back program in accordance with the authorisation granted to the Board of Directors on the Annual General Meeting held 16 April 2020. The authorisation covers share buy-backs up to a maximum of 10% of the Company's share capital at any given time and is valid until 16 April 2025.Purposes: The purposes of the...

NTG Nordic Transport Group publishes interim report for H1 2023

Company announcement no. 37 – 233 August 2023 NTG Nordic Transport Group publishes interim report for H1 2023The interim report for H1 2023 is enclosed.In connection with publication of the results for H1 2023, a conference call will be hosted on 4 August 2023 at 10:00 AM CEST. The conference call will be held in English and can be followed live via NTG's website ; investor.ntg.com. Additional information For additional information, please contact: Investor relations: ...

Update on full-year outlook for 2023

Company announcement no. 36 – 233 August 2023 Update on full-year outlook for 2023 Activity was lower than expected during Q2 2023, with a weak spot market and lower volumes. The anticipated improvement in market conditions during Q2 did not materialise, and we have yet to experience a pick-up in volumes. The lower-than-expected results are most notable in the Air & Ocean division, whereas Road & Logistics is more stable despite the weak spot market.Based on the Q2 2023...

BlueRock Therapeutics and bit.bio announce collaboration and option agreement…

"We are delighted to partner with the team at BlueRock, who are world-leaders in iPSC-derived cell therapies, and together address the significant unmet needs of these patients." said Mark Kotter, MD PhD, CEO of bit.bio. "Today's announcement marks an important milestone for bit.bio. As well as providing significant financial contributions, our collaboration is a testament to the unique capabilities of bit.bio's team." "We are delighted to partner with the team at…

COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business…

Highlights: COMP360 Phase 3 pivotal program ongoing and on trackCPT ®III code for in-person psychedelic therapy support accepted by the American Medical AssociationCash position at June 30, 2023 of $148.2 millionTerm loan facility up to $50 million securedConference call today at 8:00 am ET (1:00 pm UK)COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, reported...

KOOL 'N' SOOTHE NIGHT COOLING SPRAY - BACK IN STOCK ON AMAZON AFTER STRONG…

The product, from the makers of the Kool 'N' Soothe Migraine cooling gel sheets, offers a new solution to the increasingly hot UK summer nights. A few sprays on your bed sheets, duvet, or the inside of your nightwear (but not underwear) can make your fabrics cool to the touch, promoting a comfortable and cool sleep. The L-menthol formula provides a cooling sensation activated by sweat, helping users stay comfortably cool with minimal effort. Given the rising summer temperatures in the...

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT JULY 2023

Accumulated revenue for January – July 2023 increased by 23 % to SEK 950.9 (774.4) million. Accumulated revenue for January –July 2023increased by 23 % toSEK 950.9(774.4) million. Revenues were distributed as follows: Countries in regions: -The Nordics:Denmark, Faroe Island,Finland,Iceland,Norway,Sweden- Central Europe :Austria,Germany,Switzerland- East Europe :Czech Republic,Slovakia,Hungary,Poland,Romania-South &West Europe...

Nexstim Receives an NBS 5 System Order from a German Hospital

Press release, Helsinki, 3 August 2023 at 12PM (EEST) Nexstim Receives an NBS 5 System Order from a German Hospital Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS 5 system from a hospital in Germany.Nexstim's NBS (Navigated Brain Stimulation) System 5 is CE marked and FDA approved for presurgical mapping of the speech and motor cortices of the brain. In addition to its motor and speech mapping features, this specific system also...

XRP Healthcare and Spiritus Medical Partner to Revolutionize Healthcare in…

The SPIRITUS VITALITY Ventilator was developed byNASA's Jet Propulsion Laboratory during the COVID pandemic times and made in theUSA. The original design was approved by the Food and Drug Administration (FDA) for Emergency Use Authorization and is a crucial technology that can address the critical shortage of conventional ventilators inAfrica. Its rigorous testing and evaluation ensure its reliability and efficacy in treating almost all patients needing mechanical ventilation...

VALNEVA Declaration of shares and voting rights - July 31, 2023

VALNEVADeclaration of shares and voting rights July 31 , 2023__________________________________________________________________________________________Company name: VALNEVA Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France) Regulated market of Euronext Paris - Compartment BDeclaration date: August 3, 2023 Number of sharescomposing the share capital of ValnevaTotal number of voting rights including suspended voting rights* Description of the...

LIfT BioSciences reports a substantial increase in cancer killing with the…

LIfT BioSciences reports a substantial increase in cancer killing with the addition of aHER2 targetingCARto its IMAN cell therapyPositive data supports the potential of the iN-LIfT platform to produce a variety of genetically engineered CAR-IMANs to enhance killing and more targeted immunomodulation for different tumour targetsLIfT entersinto licensing discussions for its N-LIfT platform with biopharma companies ...

Ultimovacs Announces Completed Enrollment in FOCUS Phase II Clinical Trial of…

The randomized, investigator-initiated FOCUS trial has completed enrollment of 75 patients with recurrent or metastatic head and neck squamous cell carcinoma The study will provide randomized data on the benefit of UV1 vaccination as add-on to standard pembrolizumab treatmentTopline results, including overall survival, will be provided to the Company by the Principal Investigator 12 months after the last patient received first dose, expected in second half of 2024Oslo, 3 August...

Mithra Receives EUR 1.25 Million Milestone Payment from Fuji Pharma under…

Mithra Receives EUR 1.25 Million Milestone Payment from Fuji Pharma underEstelle ® LicensingAgreement Relates to completion of the interim clinical study reports of Phase 3 trials in patients with dysmenorrhea or endometriosisMarks strong progress in 2016 agreement and further boosts Mithra cash positionAdditional EUR 12.5 million milestone payments scheduled prior to commercializationMithra eligible for revenue from supply of the...

Bavarian Nordic Receives USD 120 Million Contract for the Manufacturing of…

Contract award will support manufacturing of new bulk vaccine to partly replenish the inventory used for the mpox outbreak in 2022Aims to strengthen the long-term U.S. stockpiling of smallpox vaccinesCompany upgrades its financial guidance for 2023COPENHAGEN, Denmark, August 3, 2023– Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U...

Fagron delivers strong performance with 13% topline growth and 14% increase in…

Regulated information – inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 3 August 2023 – 7AM CET Fagron delivers strong performance with 13% topline growth and 14% increase in REBITDA for first half of 2023 Fagron, the leading global player in pharmaceutical compounding today publishes its first half results for the period ending 30 June 2023. Key Highlights Strong topline performance with 13.1% reported revenue growth (12.1% at CER)and 8.4% organic revenue...

BioSenic S.A. : Information on the total number of voting rights and shares

REGULATED INFORMATION Mont-Saint-Guibert, Belgium, August 2 , 2023, 7.00 am CEST – BIOSENIC(Euronext Brussels and Paris: BIOS), the innovative company addressing unmet medical needs in in the areas of innate immunity, inflammation and organ/function repair, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares following the conversion of convertible bonds. The following information is published in accordance with...

Addex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7…

Discovery collaboration on track to deliver clinicalcandidates for IND enabling studies in 2024 Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, August 3 , 2023 -Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that its collaboration agreement with Indivior PLC (LON: INDV) for the discovery of novel oral gamma-aminobutyric...

Roche expands long-term alliance with Sysmex

"We are delighted to expand our 25-year partnership with Sysmex in the area of hematology and in exploring more sustainable diagnostics solutions. Roche and Sysmex both have a long-standing history of delivering reliable and innovative solutions for patients and I am very happy to see this collaboration grow," said Matt Sause, CEO of Roche Diagnostics. "We are delighted to expand our 25-year partnership with Sysmex in the area of hematology and in exploring more sustainable…

Bridge to Life Divests Certain Assets to TransMedics

Piper Sandler & Co. acted as financial advisor to Bridge to Life. Canaccord Genuity LLC acted as financial advisor to TransMedics. Cooley LLP acted as legal advisor to Bridge to Life. Ropes & Gray LLP acted as legal advisor to TransMedics. Piper Sandler& Co. acted as financial advisor to Bridge to Life. Canaccord Genuity LLC acted as financial advisor to TransMedics. Cooley LLP acted as legal advisor to Bridge to Life. Ropes & Gray LLP acted as legal advisor to TransMedics…

Atherosclerosis Market to Witness Growth by 2032, Estimates DelveInsight |…

Key Takeaways from the Atherosclerosis Market Report Key Takeaways from the Atherosclerosis Market Report Discover which therapies are expected to grab the major atherosclerosis market share @Atherosclerosis Market Report Atherosclerosis Overview Atherosclerosis is a common cardiovascular disease that involves the buildup of fatty deposits, cholesterol, and other substances on the inner walls of arteries. Over time, these deposits can lead to the formation of plaque, which...

Casino Group: Release of the H1 2023 financial report

RELEASE OF THE HALF YEAR 2023FINANCIAL REPORT The Group has released its half year 2023 financial report, in French, on its website. It is available following this link: https://www.groupe-casino.fr/wp-content/uploads/2023/08/Rapport-financier-S1-2023.pdfANALYST AND INVESTOR CONTACTSChristopher Welton– +33 (0)1 53 65 64 17 cwelton.exterieur@groupe-casino.fr or +33 (0)1 53 65 24 17 IR_Casino@groupe-casino.fr PRESS CONTACTSCasino Group – Communications...

Bioimpedance Analyzers Market worth $927 million | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=144536297 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=144536297 Browse in-depth TOC on "Bioimpedance Analyzers Market" 126 - Tables 32 - Figures 170 - Pages Bioimpedance Analyzers Market Scope: Multi-frequency bioimpedance analyzers segment is expected to account for the largest share in 2022. The bioimpedance analyzers...

Vascular Access Device Market worth $7.9 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=122149686 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=122149686 Browse in-depth TOC on "Vascular Access Device Market" 69 - Tables 40 - Figures 141 - Pages Vascular Access Device Market Scope: The central vascular access device segment is accounted for largest share of the market during the forecast period On the basis of...

Collagen Market size worth $ 4.92 Billion, Globally, by 2028 at 4.99% CAGR…

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=25556 Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=25556 Browse in-depth TOCon" Collagen Market " 202 - Pages 126 – Tables 37 – Figures Key Players, Competitive Landscape, and Market Outlook for the Collagen Market: Opportunities and Growth Prospects The popularity of vegan and vegetarian diets, expanding public knowledge of the health benefits...

Altri Comunicati